Market Intelligence, Clinical Progress, and High-Purity Reagents for Next-Generation Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IL-15RA drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL-15RA ECD-Fc / Sushi Domain Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View IL-15RA Products |
| Gene Delivery | IL-15RA Promise-ORF / Lentivirus Premade Particles Full-length ORF for stable cell lines and trans-presentation assays. |
View IL-15RA Products |
| Benchmark Ab | Anti-IL-15RA Recombinant Antibody Recombinant positive control for binding and blocking assays. |
View IL-15RA Products |
| Validator | IL-15RA siRNA Set For target knockdown verification in functional assays. |
View IL-15RA Products |
| Related Target A | IL-15 Synergistic ligand forming the high-affinity trans-presentation complex. |
View IL-15 Products |
| Related Target B | IL-2RB (CD122) Shared receptor subunit critical for downstream JAK/STAT signaling validation. |
View IL-2RB Products |
| Related Target C | IL-2RG (CD132) Common gamma chain involved in the functional signaling complex. |
View IL-2RG Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Sushi Domain Conformational Integrity | HEK293 expressed recombinant proteins preserve native disulfide bonds and glycosylation patterns. |
| Trans-presentation Assay Setup | High-titer Lentivirus Premade Particles enable stable IL-15RA expression on target cells. |
| Lack of Standardization Controls | Sequence-verified clinical benchmark antibodies available as reference standards. |
| Off-Target Cross-Reactivity | Purity verified by SDS-PAGE (>95%) and mass spectrometry to eliminate assay interference. |
Live IL-15RA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IL-15RA therapeutics is intensifying, with major players shifting focus from traditional cytokine therapies to IL-15/IL-15RA fusion complexes (superagonists) and bispecific immunocytokines. As first-generation therapies like Nogapendekin alfa inbakicept (N-803) secure regulatory approvals, the next wave of R&D is targeting tumor-localized delivery and combination regimens with immune checkpoint inhibitors to overcome the immunosuppressive tumor microenvironment.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| IL-15/IL-15RA Fusion (Superagonist) | ImmunityBio, Hangzhou Jiuyuan Gene Engineering | Bladder Cancer, Solid Tumors | Heterodimer Validation (Need High-Purity Sushi Domain & IL-15 Proteins) |
| Bispecific/Immunocytokine | AstraZeneca, Innovent Biologics | Non-Small Cell Lung Cancer (NSCLC) | Targeting Selectivity & Binding Kinetics (Need SPR-grade ECD-Fc Proteins) |
| mRNA / Cell Therapy | Moderna, BioNTech | Advanced Solid Malignancies | In vitro Expression Verification (Need Stable Cell Line construction via Lentivirus) |